Inhibitory effects of furoquinoline alkaloids from Melicope confusa and Dictamnus albus against human phosphodiesterase 5 (hPDE5A) in vitro

Archives of Pharmacal Research

Volumn 28, Issue 6, 2005, Pages 675-679

  Nam, Kung Woo ^a,b   Je, Kang Hoon ^b   Shin, Young Jun ^a   Sam, Sik Kang ^b   Mar, Woongchon ^b  

^a Jung San Biotechnology Institute   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

cGMP; Furoquinoline alkaloids; hPDE5A; Smooth muscle

Indexed keywords

ALKALOID; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; ENZYME INHIBITOR; QUINOLINE DERIVATIVE;

ARTICLE; BIOSYNTHESIS; CHEMISTRY; COMPARATIVE STUDY; DICTAMNUS; DRUG ANTAGONISM; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MOLECULAR CLONING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; RUTACEAE; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ALKALOIDS; BASE SEQUENCE; CELL LINE, TUMOR; CLONING, MOLECULAR; DICTAMNUS; ENZYME INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; QUINOLINES; RUTACEAE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 24944494133     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02969357     Document Type: Article

References (25)

1. Blount, M. A., Beasley, A., Zoraghi, R., Sekhar, K. R., Bessay, E. P., Francis, S. H., Corbin, J. D., Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol. Pharmacol., 66, 144-152 (2004).
2. Boolell, M., Allen, M. J., Ballard, S. A., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Osterloh, I. H., Gingell, C., Sildenafill: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res., 8, 47-52 (1996).
3. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976).
4. Chen, Y., Traverse, J. H., Hou, M., Li, Y., Du, R., and Bache, R. J., Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am. J. Physiol. Heart Circ. Physiol., 284, H1513-H1520 (2003).
5. Chen, Z., Zhang, J., and Stamler, J. S., Identification of the enzymatic mechanism of mitroglycerin bioactivation. Proc. Natl. Acad. Sci. U.S.A., 99, 8306-8311 (2002).
6. Crocker, I. C. and Townley, R. G., Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs Today (Barc), 35, 519-535 (1999).
7. Fink, T. L., Francis, S. H., Beasley, A., Grimes, K. A., and Corbin, J. D., Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J. Biol. Chem., 274, 34613-34620 (1999).
8. Francis, S. H., Bessay, E. P., Kotera, J., Grimes, K. A., Liu, L., Thompson, W. J., and Corbin, J. D., Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J. Biol. Chem., 277, 47581-47587 (2002).
9. Funayama, S., Tanaka, R., Kumekawa, Y., Noshita, T., Mori, T., Kashiwagura, T., and Murata, K., Rat small intestine muscle relaxation alkaloids from Orixa japonica leaves. Biol. Pharm. Bull., 24, 100-102 (2001).
10. Hirose, R., Okumura, H., Yoshimatsu, A., Irie, J., Onoda, Y., Nomoto, Y., Takai, H., Ohno, T., and Ichimura, M., KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. Eur. J. Pharmacol., 431, 17-24 (2001).
11. Kim, D. K., Lee, J. Y., Lee, N., Ryu, D. H., Kim, J. S., Choi, J.Y., Ryu, J. H., Kim, N. H., Im, G. H., Choi, W. S., and Kim, T. K., Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5′-sulfonamide moiety of a phenyl ring. Bioorg. Med. Chem., 9, 3013-3021 (2001).
12. Lacas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., Chepenik, K. P., and Waldman, S., Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev., 52, 385-414 (2000).
13. Lin, C. S., Chow, S., Lau, A., Tu, R., and Lue, T. F., Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int. J. Impot. Res., 14, 15-24 (2002).
14. Mehats, C., Andersen, C. B., Filopanti, M., Jin, S. L., and Conti, M., Cyclic nucleotide phosphodieterase and their role in endocrine cell signaling. Trends Endocrinol. Metab., 13, 29-35 (2002).
15. Natochin, M. and Artemyev, N. O., An interface of interaction between photoreceptor cGMP phosphodiesterase catalytic subunits and inhibitory gamma subunits. J. Biol. Chem., 271, 19964-19969 (1996).
16. Rybalkin, S. D., Rybalkina, I. G., SHimizu-Albergine, M., Tang, X. B., and Beavo, J. A., PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO Journal, 223, 469-478 (2003).
17. Sausbier, M., Schubert, R., Voigt, V., Hirneiss, C., Pfeifer, A., Korth, M., Kleppisch, T., Ruth, P., and Hormann, F., Mechanisms of NO/cGMP-dependent vasorelaxation. Circ. Res., 87, 825-830 (2000).
18. Schmit, D., Dent, G., and Rabe, K. F., Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Clin. Exp. Allergy, 29, 99-109 (1999).
19. Tejada, I. S., Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int. J. Impot. Res., 16, S40-S42 (2004).
20. Turbo, I. V., Haik, T. L., McAllister-Lucas, L. M., Burns, F., Francis, S. H., and Corbin, J. D., Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodieaterases. A putative NKXnD motif for cGMP biding. J. Biol. Chem., 271, 22240-22244 (1996).
21. Turko, I. V., Ballard, S. A., Francis, S. H., and Corbin, J. D., Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type5) by sildenafil and related compounds. Mol. Pharmacol., 56, 124-130 (1999).
22. Uckert, S., Kuthe, A., Stief, C. G., and Jonas, U., Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J. Urol., 19, 14-22 (2001).
23. Wang, M., Urenjak, J., Fedele, E., and Obrenovitch, T. P., Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP. Biochem. Pharmacol., 67, 1619-1627 (2004).
24. White, D. G. and Martin, W., Differential control and calciumdependence of production of endothelium- derived relaxing factor and prostacyclin by pig arotic ndothelial cells. Br. J. Pharmacol., 97, 683-690 (1989).
25. Wyatt, T. A., Naftilan, A. J., Francis, S. H., and Corbin, J. D., ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am. J. Physiol., 274, H448-H455 (1998).